The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Psychopathology in methamphetamine-dependent adults 3 years after treatment
Open accessAbstract
INTRODUCTION AND AIMS: Although psychiatric symptoms are frequently observed in methamphetamine (MA) users, little is known about the prevalence of psychiatric disorders in MA-dependent individuals. This is the first study to examine the association of psychiatric disorders with substance use and psychosocial functioning in a large sample of MA users 3 years after treatment. We predicted that psychiatric diagnoses and severity would be associated with substance use and poorer overall functioning over the 3 year post-treatment course. DESIGN AND METHODS: Participants (N = 526) received psychosocial treatment for MA dependence as part of the Methamphetamine Treatment Project and were reassessed for psychosocial functioning and substance use at a mean of 3 years after treatment initiation. DSM-IV psychiatric diagnoses were assessed at follow-up using the Mini-International Neuropsychiatric Interview. Psychosocial functioning was assessed using the Addiction Severity Index. RESULTS: Overall, 48.1% of the sample met criteria for a current or past psychiatric disorder other than a substance use disorder. Consistent with prior reports from clinical samples of cocaine users, this rate was largely accounted for by mood disorders, anxiety disorders and antisocial personality. Those with an Axis I psychiatric disorder evidenced increased MA use and greater functional impairment over time relative to those without a psychiatric disorder. DISCUSSION AND CONCLUSIONS: This initial investigation of psychiatric diagnoses in MA users after treatment indicates elevated rates of Axis I and II disorders in this population and underscores the need for integrated psychiatric assessment and intervention in drug abuse treatment settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glasner-Edwards et al 18 identified that people who experience depressive symptoms and use MA may have a poorer prognosis for both conditions and may experience worse treatment outcomes.”
From Protocol for a systematic review of psychological treatment for methamphetamine use: An analysis of methamphetamine use and mental health symptom outcomes (2017) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
An Improved Diagnostic Evaluation Instrument for Substance Abuse Patients
McLellan, A. T., Luborsky, L. B., WOODY, G. E., & Brien, C. P. O. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,163
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
Regier, D. A., Farmer, M. E., Rae, D. S., et al. (1990) · PubMed · Cited by 1,913
Kessler, R. C., Nelson, C. B., McGonagle, K. A., Edlund, M. J., Frank, R. G., & Leaf, P. J. (1996) · American Journal of Orthopsychiatry · doi:10.1037/h0080151 · Cited by 1,378
Abstinence Symptomatology and Psychiatric Diagnosis in Cocaine Abusers
Gawin, F. H. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020013003 · Cited by 1,143
Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0211 · Cited by 934 · cited 3×
“Prevalence rates of these disorders in cocainedependent adults are particularly high, with estimates of lifetime mood disorders exceeding 60% and anxiety disorders ranging between 45% and 50% in this population [6].”
A 33-Year Follow-up of Narcotics Addicts
Hser, Y., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.503 · Cited by 849
Research works printed but not linked: 1
- 10.1080/10550490490436055 · DOI
Cited by
Sorted by citations
Items 101–128 of 128
Club Drugs and Novel Psychoactive Substances
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106
A Brief History of NPS Production and Distribution
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.003
Stimulant Drugs: Synthetic Cathinones
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.011
Stimulant Drugs: Methamphetamine
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.009
Classification Framework for Club Drugs and NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.004
Stimulant Drugs: Amphetamine-Type Stimulants
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.008
Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.013
The Clinical Challenge of Club Drugs and NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.005
Depressant Drugs: Benzodiazepine NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.015
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.007
Synthetic Cannabinoid Receptor Agonists (SCRAs)
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.017
Stimulant Drugs: MDMA and Drugs with Similar Effects
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.010
What Are Club Drugs and NPS and Why Are They Important?
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.002
Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.014
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.019
Depressant Drugs: Introduction
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.012
Depressant Drugs: Ketamine and Its Analogues
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.016
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.001
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.018
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.020
Song, Z., Dong, F., Liu, Y., Liu, G., Li, B., Pang, X., An, K., Li, D., Chen, S., Xing, W., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.878859
Disorders Due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_26-1
Novin, M. H., Bousari, A. C., Radmand, S., & Pourramzani, A. (2024) · Journal of Substance Use · doi:10.1080/14659891.2024.2423616
Galhenage, J., Isuru, A., Dayabandara, M., & Hanwella, R. (2026) · Indian Journal of Psychological Medicine · doi:10.1177/02537176261451022
Sighaldeh, S. S., Zarghami, F., Shahryari, A., Mohammadinia, A., Ebrahimi, M., Jorjani, T., Hamrah, M. S., & Charkazi, A. (2020) · Figshare · doi:10.6084/m9.figshare.13279574
Sex-specific Trends in Methamphetamine Use in the United States, 2002–2022
Joe, S., Carley, J. A., Kim, E.-J., Soltani, M., & Marienfeld, C. B. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001697
Kadınlarda Bağımlılığın Gelişimi: Kullanım Dinamikleri, Yaşam Etkileri ve Müdahale İhtiyaçları
Gürel, M., Daşgın, A., Aktürk, İ., & Yaman, Ö. M. (2026) · Anadolu Üniversitesi Sosyal Bilimler Dergisi · doi:10.18037/ausbd.1815553
The bidirectional predictive association between methamphetamine use and depression
Tran, L. T., Clare, P. J., Degenhardt, L. J., Lubman, D. I., Berk, M. P., Carter, G. L., Arunogiri, S., Turner, A., Dean, O. M., Kelly, P. J., et al. (2026) · Addiction · doi:10.1111/add.70668
Metadata
- Authors
- GLASNER‐EDWARDS, S., MOONEY, L. J., MARINELLI‐CASEY, P., HILLHOUSE, M., ANG, A., RAWSON, R. A., & THE METHAMPHETAMINE TREATMENT PROJECT CORPORATE AUTHORS
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Drug and Alcohol Review
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 29
- Issue
- 1
- Pages
- 12-20
- ISSN
- 0959-5236 (ISSN-L)
- 1465-3362
- PMC
- PMC3772133
- OpenAlex
- W1941604713
- Cited by
- 128
- References
- 35
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 32 · 2019: 2 · 2018: 9 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 12 · 2013: 9 · 2012: 7
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Drug and Alcohol Review (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (K23DA020085)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Youth, Drugs, and Violence
- Keywords
- methamphetamine dependence, psychiatric comorbidity, mood disorders, anxiety disorders, antisocial personality disorder, psychosocial functioning, substance use
- MeSH terms
- Adult, Mental Disorders, Female, Follow-Up Studies, Humans, Male, Methamphetamine, Psychiatric Status Rating Scales, Severity of Illness Index, Prevalence, Diagnosis, Dual (Psychiatry), Amphetamine-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
